ASCO 2019: Pazopanib Fails to Show Benefit for Metastatic Renal Cell Carcinoma Following Metastasectomy
An unmet need remains for effective therapy in this clinical setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.